Equinix ( EQIX) estimates, target raised at Citigroup. Shares of EQIX now seen reaching $150, according to Citigroup. Estimates also increased on favorable revenue growth prospects. Buy rating.HCA ( HCA) estimates, target boosted at Goldman. Shares of HCA now seen reaching $27, according to Goldman Sachs. Estimates also upped, as the company is realizing a lower tax rate. Neutral rating. HCA estimates, target raised at UBS. Shares of HCA now seen reaching $35, according to UBS. Estimates also increased on strong Q4 estimates. Buy rating. Health Net ( HNT) numbers increased at BMO. HNT estimates were raised through 2013, BMO Capital said. Company has good operating momentum. Market Perform rating and new $39 price target. Humana ( HUM) numbers lowered at Jefferies. Shares of HUM now seen reaching $103, Jefferies said. Estimates also lowered as MCOs have traded poorly following earnings releases this season. Buy rating. Humana estimates, target reduced at Goldman. Shares of HUM now seen reaching $103, according to Goldman Sachs. Estimates also cut, given the company's new guidance. Buy rating. NCR ( NCR) estimates, target upped at Goldman. NCR estimates were boosted through 2013, Goldman Sachs said. To match the company's new guidance. Buy rating and new $21 price target. Nielsen Holdings ( NLSN) numbers lowered at Citigroup. Shares of NLSN now seen reaching $35, according to Citigroup. Estimates also lowered on tougher FX and D&A expenses. Buy rating. Nuance Communications ( NUAN) target raised at Oppenheimer. Shares of NUAN now seen reaching $34, Oppenheimer said. Expect solid first quarter as iPhone 4S bolsters key divisions. Outperform rating. SL Green Realty ( SLG) numbers raised at UBS. Shares of SLG now seen reaching $85, according to UBS. Estimates also raised on Q4 results and slightly increased leasing assumptions. Buy rating. Towers Watson ( TW) numbers raised at Goldman. shares of TW now seen reaching $68, according to Goldman Sachs. Estimates also increased, as higher organic growth is improving margins. Neutral rating. USG ( USG) estimates, target raised at Goldman. Shares of USG now seen reaching $8, according to Goldman Sachs. Estimates also increased, given a better pricing environment. Sell rating. Veeco Instruments ( VECO) numbers cut at Goldman. VECO estimates were reduced through 2013, Goldman Sachs said. Company has limited visibility. Neutral rating and new $26 price target. >To submit a news tip, email: firstname.lastname@example.org.
Twitter and become a fan on Facebook.